BR112014011563B1 - Método para determinar um risco aumentado de carcinoma de células escamosas de cabeça e pescoço (hnscc) em um indivíduo humano infectado com papiloma vírus humano (hpv), e kit - Google Patents

Método para determinar um risco aumentado de carcinoma de células escamosas de cabeça e pescoço (hnscc) em um indivíduo humano infectado com papiloma vírus humano (hpv), e kit Download PDF

Info

Publication number
BR112014011563B1
BR112014011563B1 BR112014011563-0A BR112014011563A BR112014011563B1 BR 112014011563 B1 BR112014011563 B1 BR 112014011563B1 BR 112014011563 A BR112014011563 A BR 112014011563A BR 112014011563 B1 BR112014011563 B1 BR 112014011563B1
Authority
BR
Brazil
Prior art keywords
hnscc
hpv
sample
antibody
kit
Prior art date
Application number
BR112014011563-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014011563A2 (pt
Inventor
Elizabeth Franzmann
Lutecia Pereira
Isildinha M. Reis
Robert C. Duncan
Original Assignee
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Miami filed Critical University Of Miami
Publication of BR112014011563A2 publication Critical patent/BR112014011563A2/pt
Publication of BR112014011563B1 publication Critical patent/BR112014011563B1/pt

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
BR112014011563-0A 2011-11-15 2012-11-15 Método para determinar um risco aumentado de carcinoma de células escamosas de cabeça e pescoço (hnscc) em um indivíduo humano infectado com papiloma vírus humano (hpv), e kit BR112014011563B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161559974P 2011-11-15 2011-11-15
US61/559,974 2011-11-15
US201261654595P 2012-06-01 2012-06-01
US61/654,595 2012-06-01
PCT/US2012/065282 WO2013074793A1 (en) 2011-11-15 2012-11-15 Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma

Publications (2)

Publication Number Publication Date
BR112014011563A2 BR112014011563A2 (pt) 2017-05-09
BR112014011563B1 true BR112014011563B1 (pt) 2022-05-24

Family

ID=48430146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011563-0A BR112014011563B1 (pt) 2011-11-15 2012-11-15 Método para determinar um risco aumentado de carcinoma de células escamosas de cabeça e pescoço (hnscc) em um indivíduo humano infectado com papiloma vírus humano (hpv), e kit

Country Status (13)

Country Link
US (3) US20140329230A1 (https=)
EP (1) EP2780714B1 (https=)
JP (1) JP6174035B2 (https=)
CN (1) CN104067126B (https=)
AU (3) AU2012340441A1 (https=)
BR (1) BR112014011563B1 (https=)
CA (1) CA2855971C (https=)
CO (1) CO6980621A2 (https=)
ES (1) ES2640532T3 (https=)
IL (1) IL232556A (https=)
MX (1) MX352642B (https=)
PE (1) PE20141565A1 (https=)
WO (1) WO2013074793A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012340441A1 (en) 2011-11-15 2014-05-29 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
WO2015017692A1 (en) * 2013-07-31 2015-02-05 University Of Miami Compositions and methods for identifying a risk of cancer in a subject
WO2015026827A2 (en) * 2013-08-19 2015-02-26 University Of Notre Dame Method and composition for detection of oncogenic hpv
WO2015179712A1 (en) 2014-05-22 2015-11-26 University Of Notre Dame Du Lac Integrated membrane sensor for rapid molecular detection
WO2016209703A1 (en) * 2015-06-22 2016-12-29 The Johns Hopkins University Head and neck squamous cell carcinoma assays
JP6655243B2 (ja) * 2015-09-01 2020-02-26 国立大学法人 鹿児島大学 口腔前癌病変の検出方法
CN107092854B (zh) * 2016-02-18 2020-05-22 财团法人金属工业研究发展中心 检测细胞受人类乳头瘤病毒(hpv)感染的装置及其检测方法
GB201808839D0 (en) 2018-05-30 2018-07-11 Cancer Research Tech Ltd Method of predicting survival rates for cancer patients
WO2020018954A1 (en) * 2018-07-20 2020-01-23 Predentome, Inc. Methods and systems for oral microbiome analysis
US20220137041A1 (en) * 2019-02-26 2022-05-05 University Of Miami Device for methods of detecting cancer
US20240188897A1 (en) * 2021-04-23 2024-06-13 The University Of Chicago Machine learning based histopathological recurrence prediction models for hpv+ head / neck squamous cell carcinoma
CN120359416A (zh) * 2022-10-17 2025-07-22 伟吉朗特生物科学公司 用于口腔癌风险的方法和组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403551A (en) 1993-09-16 1995-04-04 Roche Diagnostic Systems, Inc. Assaying device and container for in field analysis of a specimen and later shipment of the unadulterated specimen
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
US5976895A (en) 1996-03-11 1999-11-02 American Biomedica Corporation Device for the collection, testing and shipment of body fluid samples
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6379620B1 (en) 1998-11-16 2002-04-30 Barry M. Tydings Assaying device and method for in field urinalysis
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
JP4563186B2 (ja) 2004-02-16 2010-10-13 理研ビタミン株式会社 耐熱性が改善されたアントシアニン色素
WO2005095987A2 (en) * 2004-03-26 2005-10-13 University Of Miami Salivary soluble cd44: a molecular marker for head and neck cancer
WO2007129999A2 (en) 2004-07-14 2007-11-15 Biospectrum, Inc. Antiproliferative peptides and antibodies for their detection
US20090197285A1 (en) 2005-11-10 2009-08-06 University Of Kentucky Lung Cancer Diagnostic Assay
WO2007133725A1 (en) 2006-05-12 2007-11-22 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
CN101230390A (zh) * 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
EP2364371A4 (en) * 2008-11-24 2012-05-02 Univ Loma Linda BIOMARKER FOR DETECTING HEADS AND HALSTUMORS
AU2012340441A1 (en) 2011-11-15 2014-05-29 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma

Also Published As

Publication number Publication date
BR112014011563A2 (pt) 2017-05-09
AU2020277155A1 (en) 2020-12-24
US20160305942A1 (en) 2016-10-20
IL232556A (en) 2017-12-31
EP2780714A1 (en) 2014-09-24
AU2018203361A1 (en) 2018-05-31
MX2014005887A (es) 2014-09-08
JP2014533372A (ja) 2014-12-11
EP2780714A4 (en) 2015-07-15
WO2013074793A1 (en) 2013-05-23
CN104067126A (zh) 2014-09-24
US20150219656A1 (en) 2015-08-06
PE20141565A1 (es) 2014-10-25
CA2855971C (en) 2022-01-04
CN104067126B (zh) 2017-04-12
US20140329230A1 (en) 2014-11-06
AU2012340441A1 (en) 2014-05-29
IL232556A0 (en) 2014-06-30
ES2640532T3 (es) 2017-11-03
US10180431B2 (en) 2019-01-15
EP2780714B1 (en) 2017-08-16
US10180430B2 (en) 2019-01-15
MX352642B (es) 2017-12-01
JP6174035B2 (ja) 2017-08-02
AU2018203361B2 (en) 2020-08-27
CA2855971A1 (en) 2013-05-23
CO6980621A2 (es) 2014-06-27

Similar Documents

Publication Publication Date Title
AU2018203361B2 (en) Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
JP5750152B2 (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
Linge et al. Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV (−) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG
Ziskin et al. In situ validation of an intestinal stem cell signature in colorectal cancer
Götz et al. Impact of HPV infection on oral squamous cell carcinoma
US20150232945A1 (en) Identification of novel pathways for drug development for lung disease
Xu et al. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma
Pankotai-Bodó et al. Routine molecular applications and recent advances in breast cancer diagnostics
Xing et al. Expression of geminin, p16, and Ki67 in cervical intraepithelial neoplasm and normal tissues
Ferris et al. Rapid molecular detection of metastatic head and neck squamous cell carcinoma as an intraoperative adjunct to sentinel lymph node biopsy
Stancel et al. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay
Morley-Bunker et al. Assessment of intra-tumoural colorectal cancer prognostic biomarkers using RNA in situ hybridisation
Zhang et al. Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence—a retrospective cohort study
Zhu et al. Exploration of traditional Chinese medicine comprehensive treatment of triple negative breast cancer based on molecular pathological mechanism
Kristiani et al. WNT/β-Catenin signaling pathway and clinicopathological factors in advanced stage non-small cell lung cancer: a multicenter study
Liu et al. Long non-coding RNA as a potential diagnostic biomarker in oral squamous cell carcinoma: A systematic review and meta-analysis
KR102621347B1 (ko) p53 단백질 수준 또는 이를 암호화하는 유전자의 mRNA 발현 수준 측정 제제를 포함하는 위암 예측 또는 진단용 조성물
Shi et al. Association between clinical characteristics and the diagnostic accuracy of circulating single‐molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma
ES2381729B1 (es) Test predictor de supervivencia global de adenocarcinoma de pulmón
Xie et al. An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer: Molecular Diagnostics
Koh et al. PD-L1 expression assessed by four FDA-approved PD-L1 immunohistochemical assays in clear cell renal cell carcinoma: concordance and association with prognosis
Zhu et al. Profiles of blood biomarkers in lung cancer
Gutierrez et al. Pathologic evaluation of axillary dissection specimens following unexpected identification of tumor within sentinel lymph nodes
CN120796474A (zh) Mpp2基因作为结肠癌预后标志物及治疗靶点的应用
CN116008559A (zh) Mcm6作为emzl远处复发的病理预后标记物的应用

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/11/2012, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2748 DE 05-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.